Immune Design Corp. (NASDAQ:IMDZ) Earning Positive Media Coverage, Analysis Finds

Press coverage about Immune Design Corp. (NASDAQ:IMDZ) has trended positive this week, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Immune Design Corp. earned a media sentiment score of 0.44 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the stock’s share price in the next several days.

IMDZ has been the topic of a number of analyst reports. Cowen and Company reiterated a “buy” rating on shares of Immune Design Corp. in a research note on Tuesday, June 6th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $18.00 price objective (up from $16.00) on shares of Immune Design Corp. in a report on Friday, May 19th. ValuEngine raised Immune Design Corp. from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Finally, Zacks Investment Research raised Immune Design Corp. from a “sell” rating to a “hold” rating in a report on Thursday, May 18th.

Immune Design Corp. (NASDAQ IMDZ) traded down 2.70% during mid-day trading on Monday, hitting $9.00. The stock had a trading volume of 19,786 shares. The company’s market cap is $230.14 million. Immune Design Corp. has a 12 month low of $4.50 and a 12 month high of $11.10. The firm’s 50-day moving average is $7.55 and its 200 day moving average is $6.40.

COPYRIGHT VIOLATION WARNING: This report was first reported by WKRB News and is owned by of WKRB News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Insider Buying and Selling by Quarter for Immune Design Corp. (NASDAQ:IMDZ)

This story was originally published by WKRB News ( and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with's FREE daily email newsletter.


Leave a Reply

© 2006-2017 WKRB News.